Identification of ap-directed inhibitory activity.

Plasma from 7 patients with inhibitor activity against the apdomain, the A3 domain, or both was defined by a decrease in HP30 cross-reactivity to <40% and at least a 15% difference in cross-reactivity between HP32 and HP33 using the data in Table 1. Data are expressed as mean cross-reactivity and SD, as described in “Materials and Methods.”